1 unknown. 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Unknown 1 |
Follow HBV: new trials by email Literature Review of HBV trials Research Report on HBV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy and Safety of Rifaximin Treatment Rifaximin 200 mg, Standard Treatment without Rifaximin - Liver Failure, Acute on Chronic, Hepatic Encephalopathy | Early Phase 1 | Unknown | Sun Yat-sen University | 124 | 2023-03-09 | 2023-03-28 |
Acute-On-Chronic Liver Failure (1) · Hepatic Encephalopathy (1) · Hepatitis B (1)
Blood-Borne Infections (1) · Brain Diseases (1) · Brain Diseases, Metabolic (1) · Central Nervous System Diseases (1) · Communicable Diseases (1) · DNA Virus Infections (1) · Digestive System Diseases (1) · Hepadnaviridae Infections (1) · Hepatic Insufficiency (1) · Hepatitis (1) · Hepatitis, Viral, Human (1) · Infections (1) · Liver Diseases (1) · Liver Failure (1) · Liver Failure, Acute (1)
Rifaximin (1)
China (1)
PMID 10898704, PMID 20335583, PMID 21157444, PMID 23993913, PMID 25819304, PMID 26084406, PMID 27512927, PMID 28902040, PMID 28994123, PMID 31172417, PMID 31988585, PMID 32004593, PMID 32781201, PMID 33385299, PMID 33421158, PMID 34006193, PMID 35220659